Sector News

Valeant's Bausch + Lomb plant getting $150M in investments, up to 200 jobs

October 15, 2015
Life sciences

Valeant Pharmaceuticals has been pumping out a lot of products at its Bausch + Lomb plant in South Carolina, reaching the 4 billion bottle mark this week.

The company marked the occasion by announcing plans to invest in expansions that will add as many as 200 jobs over 5 years.

Valeant CEO J. Michael Pearson showed up at the plant, which manufactures products that include the Boston and ReNu lines of contact lens solutions, to share the news. According to the announcement, the company will make an immediate investment of about $25 million to add an another line at the facility. Coupled with earlier investments in the facility, the expansion will allow the plant to add another 40 million units, a 20% production boost. That will also lead to hiring another 30 employees to the 500 person workforce. The Canadian-based company will receive incentives that include a property tax break on the expansion.

But there will be more in coming years, Pearson told employees. The company is looking to invest approximately $90 million over the next two years, and about $150 million over the next 5. If realized, those investments will mean the need for another 150 to 200 workers.

Pearson said that reaching the 4-billion bottle milestone was a testament to the “enormous impact that the facility has had across the globe.” Valeant bought the company in 2013, paying investment firm Warburg Pincus $4.5 billion and spending another $4.2 billion to pay the company’s outstanding debt.

Not everything was as upbeat this week for Pearson. The company Thursday acknowledged receiving subpoenas from two different offices of the U.S. Attorney seeking info on price hikes. The company has found itself on a hot seat with members of Congress who want explanations for Valeant’s decision to jack up the prices of its drugs this year an industry-leading average of 65.6%. They are particularly interested in hearing about two drugs, Isuprel and Nitropress, for which Valeant increased the prices 525% and 212%, respectively.

By Eric Palmer

Source: Fierce Pharma Manufacturing

comments closed

Related News

November 28, 2021

Founder-led biotech is making space for ideas—and diverse leaders—where it didn’t exist before

Life sciences

Decades ago, the founder-led biotech was rare and considered the tougher path to follow. Now there is a trend of founder-led biotechs that have risen in prominence in recent years, going from startup to well known with lightning speed. Scientists-turned C-suite occupants know their technology inside out. They’ve got credibility both at the bench working with their research teams and in the boardrooms selling their future products.

November 28, 2021

Pfizer to become $100B behemoth next year thanks to COVID-19 drug and vaccine: analyst

Life sciences

Pfizer’s revenue could reach $101.3 billion in 2022, with major contributions coming from the company’s BioNTech-partnered COVID vaccine and an antiviral therapeutic that has shown stellar clinical data, SVB Leerink analyst Geoffrey Porges projected in a Monday note to clients.

November 28, 2021

GlaxoSmithKline takes aim at sick pay access inequities with microgrant program and new campaign

Life sciences

In a survey commissioned by GlaxoSmithKline’s consumer health division of 2,000 working people in the U.S., almost 70% admitted to clocking in while sick, often because they couldn’t afford to lose a day’s pay. Black and Latina women were 10% more likely than white women to shun taking sick time for fear of fallout from their boss, according to the company’s 2021 Temperature Check Report.

Send this to a friend